Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been highlighted in a NetworkNewsAudio editorial for its novel approach to treating multiple sclerosis (MS), a chronic neurodegenerative disease affecting millions worldwide. The audio feature, titled “Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis,” accompanies a previously published editorial that underscores the growing demand for therapies that go beyond symptom management. The global MS therapeutics market is projected to reach $38.62 billion by 2030, according to the editorial, reflecting the urgent need for disease-modifying treatments that can alter the course of the disease.
Quantum BioPharma’s lead candidate, Lucid-MS, is a patented, first-in-class drug candidate designed to target the myelin sheath directly. Myelin is the protective covering around nerve fibers that becomes degraded in MS, leading to a range of debilitating symptoms. The company states that Lucid-MS is intended to prevent, stop, and potentially reverse myelin degradation, addressing a significant unmet need in MS treatment. Current therapies primarily focus on managing symptoms or modulating the immune system, but few directly target the underlying mechanism of myelin repair.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS. The compound has shown the ability to prevent and reverse myelin degradation in preclinical models, positioning it as a potential breakthrough in MS therapy.
In addition to its MS pipeline, Quantum has developed UNBUZZD, a product aimed at reducing alcohol cravings. The company spun out the OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains full rights to develop similar products for pharmaceutical and medical uses.
The inclusion of Quantum BioPharma in NetworkNewsAudio’s editorial highlights the potential impact of its research on the MS treatment landscape. For investors and industry leaders, the company’s focus on myelin repair represents a distinct approach that could differentiate it from existing therapies. The full press release and additional information are available at https://nnw.fm/eI6Gv. For the latest news and updates on Quantum BioPharma, visit the company’s newsroom at https://nnw.fm/QNTM.
The editorial underscores the importance of addressing the massive unmet need in MS, where patients often face limited options that fail to halt disease progression. If Lucid-MS proves effective in clinical trials, it could offer a new paradigm for treating MS by targeting the root cause of disability. This news matters because it signals a potential shift toward regenerative therapies in neurology, with implications for patients, healthcare systems, and the broader biotech industry.
